Grand Rapids – – September 11, 2026 -- Grand Rapids Community College will formally invest Dr. Kathryn A. Rogalski as its 12th president on Sept. 18, making her the first permanent female president in the institution's history since its 1914 founding.

Investiture ceremony to draw national and regional leaders on Sept. 18

The 3 p.m. ceremony at Fountain Street Church will feature Dr. DeRionne Pollard, president and CEO of the American Association of Community Colleges, which represents more than 1,000 community colleges nationwide. Guillermo Cisneros, president and CEO of the West Michigan Hispanic Chamber of Commerce, will emcee the event.

Mountain View, Calif. – September 11, 2026 -- Cyngn Inc. (Nasdaq: CYN) has flattened a layer of management and consolidated its product and engineering teams as part of a broader restructuring aimed at accelerating enterprise sales of its DriveMod autonomous vehicle technology.

Cyngn cuts management layers to speed product decisions

CEO Lior Tal said the company streamlined its organizational structure, consolidating responsibilities around its highest-priority product, customer and commercial initiatives. Cyngn is expanding AI-assisted tools across engineering and business operations, from software development and simulation to sales operations and customer support, a move it says will improve its cost structure and extend its cash runway.

Rockville, Maryland – September 11, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) will hold fireside chats at two major investor healthcare conferences in New York this month.

REGENXBIO confirms back-to-back fireside chats on September 15 and 16

The gene therapy company will participate in the Baird 2026 Global Healthcare Conference on Tuesday, September 15 at 8:30 a.m. ET, followed by the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16 at 8:30 a.m. ET. Both sessions will take place in New York, NY.

San Diego – September 11, 2026 -- Shareholder rights firm Robbins LLP has filed a class action against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of investors who purchased the biotech's securities between December 29, 2025 and June 29, 2026, after the FDA rejected the company's kidney disease drug for a second time over unresolved manufacturing deficiencies.

FDA Issues Second Rejection Citing Identical Manufacturing Flaws

On June 30, 2026, before markets opened, Unicycive disclosed that the FDA had issued a Complete Response Letter for its resubmitted New Drug Application for oxylanthanum carbonate (OLC), identifying the "same third-party manufacturing deficiencies that were identified in the previous CRL issued in June 2025." Shares fell $3.01, or 39.1%, to close at $4.69 on unusually heavy trading volume that day.

Tamarac, Fla. – September 11, 2026 -- A PuroClean Franchise Owner has surpassed $20 million in gross sales from a single location for the first time in the restoration franchise's history, according to figures disclosed in the company's Franchise Disclosure Document. The milestone underscores accelerating reinvestment across the system, with 20% of PuroClean's 2026 unit growth coming from existing Franchise Owners adding territories.

Multi-unit ownership climbs to 44% of the franchise base

Nearly half of all PuroClean Franchise Owners, 44%, now operate multiple units. The company frames this reinvestment rate as evidence of confidence in its unit-level economics and scalability.

Berlin – September 11, 2026 -- The OECD's PISA 2025 study released today shows Germany's reading and math scores continuing to decline, prompting the SPD parliamentary group to push for expanded funding of its Startchancen-Programm and a new early-childhood quality law.

PISA 2025 shows Germany's core competencies eroding further

Saskia Esken, the SPD's rapporteur for school education, said Germany's school system delivers only middling results in international comparison, with performance in reading and math continuing to drop. She noted that social background determines educational success in Germany more strongly than in almost any other industrialized country, and that disadvantaged children are the ones falling furthest behind.

Hong Kong – September 11, 2026 -- Ascletis Pharma Inc. (HKEX: 1672) has initiated a U.S. Phase I trial of ASC36, an oral amylin receptor peptide agonist for obesity, after securing Investigational New Drug clearance from the FDA.

Trial enrolls 86 participants to test safety and dosing

The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of ASC36 across single and multiple ascending oral doses in 86 participants with obesity (BMI ≥ 30.0 kg/m2) or overweight status (BMI ≥ 27.0 kg/m2). This marks the fourth Phase I peptide study Ascletis has launched in 2026.

Englewood Cliffs, N.J. – September 11, 2026 -- Modern Micro Endodontics has opened its ninth New Jersey location at 617 E. Palisades Ave, Suite 3 in Englewood Cliffs, acquiring the practice of longtime local endodontist Dr. Anthony Fasciano, DMD.

Ownership transition adds Bergen County to a nine-office New Jersey network

The deal extends Modern Micro Endodontics' specialty footprint into Bergen County, adding root canal therapy, surgical endodontics, and same-day emergency treatment for area patients and referring dentists. Dr. Fasciano, who led the Englewood Cliffs practice for many years, selected Modern Micro Endodontics as his successor and will remain with the office temporarily to support the handoff; longtime staff will continue in their roles.

Singapore – September 11, 2026 -- Appier's AI Research team has found that large language model accuracy falls by 30% to 50% when the correct response is that no valid answer exists, a gap the company says undermines trust in enterprise Agentic AI deployments.

Rockville, Md. – September 11, 2026 -- Expert.ai has been named one of five Coolest Vendors in Gartner's Coolest Vendor Innovations in Agentic AI for Banking, Part 1 report, published August 26, 2026.

Bank customers report 90% reduction in AML false positives

Expert.ai's AI suite is already deployed at 10 top banks in Italy and by global anti-money-laundering (AML) organizations, which report more than 90% screening accuracy. Customers cite a 90% reduction in AML false positives, up to 70% time savings per alert in KYC screening, and a 40% improvement in customer satisfaction.